Wyniki wyszukiwania:

The editors have asked me to write this foreword probably for two reasons: First, I have spent 35 years trying to develop radiolabeled compounds that would help diagnose and treat disease. I, and the people from my laboratory, have been much involved with developing Nan'I for the diagnosis and treatment of hyperthyroidism and well-differentiated thyroid cancer. Second, I was a participant throughout the entire symposium upon which this book is based. Our latest '311-labeled compound, l3lll metaiodobenzylguanidine, took us 13 years to develop. It has succeeded in diagnosing and treating...